glp 1 agonist and depression GLP-1s: Are We Ignoring the Psychiatric Risks? An analysis on the role

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes

A prospective study demonstrated that 12 weeks of liraglutide treatment produced significant PASI score reductions from 15.7 to 2.2 and improved DLQI scores from 21.8 to 4.1 [60]

In that analysis, patients in the semaglutide group showed improvement from baseline to week 52 in both body weight (mean 8.4% reduction

Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes

placebo with respect to resolution of MASH without worsening of fibrosis [136, 137]

For Wharton, having these pills as treatment options is a matter of accessibility